The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical ...

Detailed price information for Amylyx Pharmaceuticals Inc (AMLX-Q) from The Globe and Mail including charting and trades.

Monte Rosa Therapeutics has dosed the first participants in the Phase I trial of the NEK7-directed molecular glue degrader (MGD), MRT-8102.

Amylyx has presented new exploratory analyses from the Phase II PREVENT and Phase IIb trials of avexitide for PBH treatment.

OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress ...

3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

Snowflake wants to reduce enterprises’ reliance on data engineers and data scientists for unstructured data analysis with its new SQL functions powered by generative AI.

For part 1 participants in the dose escalation cohorts, hospitalization was required for a minimum of 36 hours after each step-up dose and the first full treatment dose; for part 1 participants in the ...

Pharmacokinetic (PK) model generated based on the single ascending dose (SAD) data and the first multiple ascending dose (MAD) cohort. Model confirms the predicted dosing regimen for phase 2 ...

TransCode Therapeutics advances Phase 1a trial of TTX-MC138 for metastatic cancer with early signs of stability and consistent PK/PD data.